Grassroots Marketing welcomes Dr. Jim Woody, CEO and Director of 180 Life Sciences, a clinical stage biotechnology company.

180 Life Sciences aims to develop SCAs that are safe, non-psychoactive and formulated to improve efficacy and bioavailability – a real alternative to unregulated cannabidiol (CBD).

Through this program, 180 Life Sciences is working on orally available SCAs, not derived from plants, to address the deleterious issues of medical cannabis. If successful, these SCAs could offer a robustly consistent and safe dosage that allows patient intake to be carefully controlled.

Advertising Inquiries: https://redcircle.com/brands

Privacy & Opt-Out: https://redcircle.com/privacy